NCT lookup

Pull any trial record directly from ClinicalTrials.gov.

Protect and Improve Cluster of Differentiation 4 (CD4) Cells and B Cells Lymphocytes

NCT04770701

WithdrawnPhase 4

Sponsor: Trieu, Nguyen Thi, M.D.

Conditions: HIV-1-infection, AIDS

Interventions: Ahah Drug, Ahah Placebo

Countries: Vietnam

This is a plant-based medication used to increase the amount, protect, and reduce HIV's impact on T and B lymphocytes.

Eligibility overview

Sex: ALL

Age: 18 Years to 60 Years

Healthy volunteers: No

Study type: INTERVENTIONAL

Eligibility criteria

Inclusion Criteria:

* Participants have a decline in CD4 + T-lymphocytes is the hallmark of HIV-1 infection.

Characterized by rapid loss of resistance: AIDS

* Dermatitis, mouth ulcers, skin rash, itching, weight loss
* HCV (+), HBV (+), Tuberculosis (+)

Exclusion Criteria:

* Cancer under all form

Locations (1)

Ho Chi Minh City, Vietnam